But in general, circulating biomarkers of insulin resistance and adipokines were at most weakly associated with CRC risk, and not clearly associated with specific subtypes of CRC based on KRAS- and BRAF-mutations and MSI status of the tumor. The gene discussed is KRAS; the disease is Insulin resistance.